Genomics and the second golden era of cancer drug development
- 30 March 2005
- journal article
- highlight
- Published by Royal Society of Chemistry (RSC) in Molecular BioSystems
- Vol. 1 (1) , 17-26
- https://doi.org/10.1039/b501751n
Abstract
The first golden era of cancer drug development was initiated in the 1940s and gave rise to the cytotoxic agents that dominate current cancer medicine. The second golden era is now underway in which cancer genomics will direct drug development.Keywords
This publication has 66 references indexed in Scilit:
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences, 2004
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- A census of human cancer genesNature Reviews Cancer, 2004
- The Cyclin-dependent Kinase Inhibitor CYC202 (R-Roscovitine) Inhibits Retinoblastoma Protein Phosphorylation, Causes Loss of Cyclin D1, and Activates the Mitogen-activated Protein Kinase PathwayCancer Research, 2004
- Mutational Analysis of the Tyrosine Kinome in Colorectal CancersScience, 2003
- Mutations of the BRAF gene in human cancerNature, 2002
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- The Hallmarks of CancerCell, 2000